New FDA Approval in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): The Belzutifan and Lenvatinib Combination
The FDA has approved the combination of belzutifan and lenvatinib for adults with advanced kidney cancer with a clear cell component (ccRCC) who have previously received a PD-1 or PD-L1 inhibitor (immunotherapy). In the LITESPARK-011 trial, the combination extended median progression-free survival from 10.6 to 14.6 months compared with cabozantinib.
24 September 2026 — The U.S. Food and Drug Administration (FDA) approved the combination of belzutifan (Welireg) and lenvatinib (Lenvima) for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor (immunotherapy).
The approval offers a new combination option for patients with advanced ccRCC whose disease progressed during or after immunotherapy. The decision is based on a randomized, active-controlled trial that compared the combination directly with cabozantinib, an effective treatment.
The LITESPARK-011 Trial and Efficacy Data
The approval is based on the results of LITESPARK-011 (NCT04586231), an open-label, randomized, active-controlled trial that enrolled 747 patients with advanced ccRCC whose disease had progressed during or after treatment with a PD-1 or PD-L1 inhibitor. Patients were randomly assigned (1:1) to the belzutifan and lenvatinib combination arm or to the cabozantinib monotherapy arm.
The key efficacy results of the trial, as assessed by an independent central review committee, were as follows:
- Progression-Free Survival (PFS): Median progression-free survival was 14.6 months in the belzutifan and lenvatinib arm versus 10.6 months in the cabozantinib arm, a statistically significant improvement in favor of the combination (hazard ratio, HR: 0.74).
- Objective Response Rate (ORR): The objective response rate was 53% in patients receiving the combination versus 40% in the control arm.
- Overall Survival (OS): Median overall survival was 33.7 months in the combination arm and 28.6 months in the control arm (HR: 0.85); however, this result did not reach the threshold for statistical significance.
Toxicity Profile
The safety profile of the treatment includes a number of toxicity warnings related to the mechanism of action of both drugs:
- Belzutifan: The prescribing information includes a boxed warning for embryo-fetal toxicity, as well as warnings for anemia and hypoxia.
- Combination use: A risk of cardiac dysfunction is noted.
- Lenvatinib: The safety profile emphasizes caution regarding hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure, proteinuria, diarrhea, fistula formation, gastrointestinal perforation, hemorrhagic events, thyroid dysfunction and impaired wound healing.
💬 Important Information for Our Patients
The next-generation targeted smart drug combination described in this article has been approved by the U.S. Food and Drug Administration (FDA); however, the official licensing and Social Security Institution (SGK) reimbursement status of these drugs in Turkey may vary depending on the active substance. Our clinic shares openly with our patients the legal conditions of access and the clinical availability of innovative treatments.
Conclusion
The combination of belzutifan and lenvatinib has become a new option in advanced kidney cancer with a clear cell component that has progressed after immunotherapy. Compared with cabozantinib, the combination extended progression-free survival with statistical significance and raised the response rate, while the difference in overall survival did not reach significance. When choosing treatment, this gain in efficacy needs to be weighed together with the distinct side effect profiles of the two drugs.
References
- U.S. Food and Drug Administration (FDA). (24 September 2026). FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component.